A New Chemical Entity (NCE) is a drug substance containing an active ingredient that has not previously been approved for marketing in a given jurisdiction.
NCEs typically represent novel molecular entities with limited human exposure history, making early development risk assessment especially important. In clinical research, NCE status influences nonclinical requirements, first-in-human strategy, dosing rationale, and safety monitoring intensity. Development programs for NCEs often emphasize careful escalation rules, comprehensive pharmacokinetics, and enhanced adverse event surveillance. Clear documentation of NCE rationale and data supports regulatory review and strengthens confidence in benefitñrisk evaluation.